Multiple Myeloma: 7-Year Experience of Applying Targeted Therapy in Novosibirsk and Its Results

Objective. To evaluate results of the 7-year experience in treatment of multiple myeloma (MM) with proteasome inhibitor (bortezomib) in the Novosibirsk Municipal Hematological Center.

Methods. 199 MM patients treated in the Novosibirsk Municipal Hematological Center over the period from July, 2006, till December, 2014, were enrolled in the study. The median age of patients was 68 years (varied from 36 to 81). 98 patients received bortezomib as the first line therapy and 101 patients as the second line.

Results. The overall response rate of the first line therapy was 78.5 %; at that, 25 % of patients achieved a complete and almost complete remission. The median time to achieve response was 72 days. With the progression or refractory MM, the efficacy of bortezomib as a part of a combined antitumor therapy was 68.3 %. Bortezomib proved to be effective when its administration was resumed by patients who had received bortezomib and other components of the combined regimen previously (overall response: 68.4 %). The median overall survival rate has not been achieved, and 7-year survival rate was 70 %. Adverse events of bortezomib were predictable and manageable; the most relevant of them included gastrointestinal and hematologic disorders, fatigue, and peripheral neuropathy.

Conclusion. Bortezomib is a highly effective drug, which plays an important role in the treatment of MM as the first and subsequent line therapies; its administration results in significant increase in patients’ overall survival.

• T.I. Pospelova Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation, 630091 ; ГБОУ «Государственный медицинский университет», Красный пр-т, д. 52, Новосибирск, Российская Федерация, 630091
• Nataliya Valer’evna Skvortsova Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation, 630091 ; ГБОУ «Государственный медицинский университет», Красный пр-т, д. 52, Новосибирск, Российская Федерация, 630091
• I.N. Nechunaeva Municipal Hospital No. 2, 21 Polzunova str., Novosibirsk, Russian Federation, 630051 ; ГБУ «Городская клиническая больница № 2», Городской гематологический центр, ул. Ползунова, д. 21, Новосибирск, Российская Федерация, 630051

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
2. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. 5th edition. Philadelphia: Lippincott-Raven; 1997.
3. Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599–605. doi: 10.1200/jco.2009.25.2114. DOI: https://doi.org/10.1200/JCO.2009.25.2114
4. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122(10):3456–63. doi: 10.1172/jci61188. DOI: https://doi.org/10.1172/JCI61188
5. El-Amm J, Tabbara IA. Emerging Therapies in Multiple Myeloma. J Clin Oncol. 2015;38(3):315–21. doi: 10.1097/COC.0b013e3182a4676b. DOI: https://doi.org/10.1097/COC.0b013e3182a4676b
6. Kumar SK, Radjkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20. doi: 10.1182/blood-2007-10-116129. DOI: https://doi.org/10.1182/blood-2007-10-116129
7. Kumar SK, et al. Survival in Myeloma Is Improving With Novel Agents. Blood (ASH Annual Meeting Abstracts). 2012:3972. DOI: https://doi.org/10.1182/blood.V120.21.3972.3972
8. Вотякова О.М. Современная терапия множественной миеломы. Бюллетень сибирской медицины. 2008;3(приложение):33–41.
9. [Votyakova OM. Modern therapy for multiple myeloma. Byulleten’ sibirskoi meditsiny. 2008;3(Suppl):33–41. (In Russ)]
10. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–72. doi: 10.1182/blood-2007-10-078022. DOI: https://doi.org/10.1182/blood-2007-10-078022
11. Montagut C, Rovira A, Mellado B, et al. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. Drugs Today (Barc.). 2005;41(5):299–315. doi: 10.1358/dot.2005.41.5.893706. DOI: https://doi.org/10.1358/dot.2005.41.5.893706
12. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301–10. doi: 10.1038/nrc780. DOI: https://doi.org/10.1038/nrc780
13. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377–80. doi: 10.1182/blood-2002-06-1768. DOI: https://doi.org/10.1182/blood-2002-06-1768
14. Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Бортезомиб (Велкейд) в комбинации с дексаметазоном в лечении рефрактерных/рецидивирующих форм множественной миеломы у пожилых больных. Онкогематология. 2010;2:40–5.
15. [Bessmel’tsev SS, Karyagina EV, Stel’mashenko LV, et al. Bortezomib (Velcade) in combination with dexamethasone in the treatment of refractory/relapsing forms of multiple myeloma in elderly patients. Onkogematologiya. 2010;2:40–5. (In Russ)]
16. Richardson PG, Barlogie B, Berenson J. еt al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–17. doi: 10.1056/nejmoa030288. DOI: https://doi.org/10.1056/NEJMoa030288
17. Richardson PG, Britmberg H, Jagannath S, et al. Characterization and reversibility of peripheral neuropaty in patients with advanced multiple myeloma treated with bortezomib. Summit and Crest study group. Hematol J. 2004;5(Suppl):S129.
18. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma a randomized, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431. doi: 10.1016/s1470-2045(11)70081-x. DOI: https://doi.org/10.1016/S1470-2045(11)70081-X
19. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115–23. doi: 10.1046/j.1365-2141.1998.00930.x. DOI: https://doi.org/10.1046/j.1365-2141.1998.00930.x
20. Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. Результаты лечения множественной миеломы препаратом бортезомиб. Онкогематология. 2009;2:35–41.
21. [Pospelova TI, Skvortsova NV, Nechunaeva IN. Results of treatment of multiple myeloma with bortezomib. Onkogematologiya. 2009;2:35–41. (In Russ)]
22. Скворцова Н.В., Поспелова Т.И., Нечунаева И.Н. и др. Эффективность повторной терапии бортезомибом у пациентов с рефрактерными и рецидивирующими формами множественной миеломы. Бюллетень Сибирского отделения Российской академии медицинских наук. 2013;33(1):76–82.
23. [Skvortsova NV, Pospelova TI, Nechunaeva IN, et al. Efficacy of repeated treatment with bortezomib in patients with refractory and relapsing forms of multiple myeloma. Byulleten’ Sibirskogo otdeleniya Rossiiskoi akademii meditsinskikh nauk. 2013;33(1):76–82. (In Russ)]
24. Скворцова Н.В., Мельникова Т.В., Мельниченко Е.В., Мишенин А.В. Эффективность таргетной терапии множественной миеломы с использованием ингибиторов протеасом. Бюллетень Сибирского отделения Российской академии медицинских наук. 2011;31(2):94–100.
25. [Skvortsova NV, Mel’nikova TV, Mel’nichenko EV, Mishenin AV. Efficacy of targeted therapy for multiple myeloma using proteasome inhibitors. Byulleten’ Sibirskogo otdeleniya Rossiiskoi akademii meditsinskikh nauk. 2011;31(2):94–100. (In Russ)]
26. Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. и др. Результаты лечения рефрактерных/рецидивирующих форм множественной миеломы. Гематология и трансфузиология. 2012;57(3):21–2.
27. [Pospelova TI, Skvortsova NV, Nechunaeva IN, et al. Results of treatment of refractory/relapsing forms of multiple myeloma. Gematologiya i transfuziologiya. 2012;57(3):21–2. (In Russ)]
28. Mateos M-V, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008;93(4):560–5. doi: 10.3324/haematol.12106. DOI: https://doi.org/10.3324/haematol.12106
29. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777–84. doi: 10.1182/blood-2005-03-1173. DOI: https://doi.org/10.1182/blood-2005-03-1173
30. NCCN GuidelinesTM Version 1. 2011 Multiple myeloma. Available from: www.nccn.org. (accessed 20.06.2015).